LAG3 and vitiligo: Per our systematic review, we identified six studies that demonstrated that the use of LAG‐3 inhibitors, whether as a single agent or in combination with other immune checkpoint inhibitors, resulted in a variety of dermatological conditions, including stomatitis, pruritus, rash, dry skin, erythema, and vitiligo.